Evidence map›Paper›PMID 33247227›Full record

ArticleCancer gene therapy2021

SON inhibits megakaryocytic differentiation via repressing RUNX1 and the megakaryocytic gene expression program in acute megakaryoblastic leukemia.

Lana Vukadin, Jung-Hyun Kim, Eun Young Park, Joshua K Stone, Nathan Ungerleider, Melody C Baddoo, Hyun Kyung Kong, Alexander Richard, Johnny Tran, Hannah Giannini and 3 more

Open access · greenAbstract read
In one paragraph

Article in Cancer gene therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Lana VukadinDepartment of Pathology, Division of Molecular and Cellular Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.
Jung-Hyun KimMitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
Eun Young ParkMitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
Joshua K StoneMitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
Nathan UngerleiderDepartment of Pathology, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA, USA.
Melody C BaddooDepartment of Pathology, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA, USA.
Hyun Kyung KongMitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
Alexander RichardMitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
Johnny TranMitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
Hannah GianniniMitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
Erik K FlemingtonDepartment of Pathology, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA, USA.
Ssang-Taek Steve LimDepartment of Biochemistry & Molecular Biology, College of Medicine, University of South Alabama, Mobile, AL, USA.ORCID http://orcid.org/0000-0003-0323-8607
Eun-Young Erin AhnDepartment of Pathology, Division of Molecular and Cellular Pathology, University of Alabama at Birmingham, Birmingham, AL, USA. eyahn@uabmc.edu.ORCID http://orcid.org/0000-0001-8795-7734
USA Mitchell Cancer Institute · USTulane University · USUniversity of Alabama at Birmingham · USUniversity of Alabama at Birmingham Hospital · USUniversity of South Alabama · US

Funding

RPMS1 circular RNAs in EBV malignanciesR01CA243793 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI FLEMINGTON, ERIK K · 2019 to 2023
$1.8M
SON-mediated RNA splicing in glioblastomaR01CA236911 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AHN, ERIN EUN-YOUNG · 2020 to 2024
$1.8M
SON-mediated gene expression and leukemiaR01CA190688 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI AHN, ERIN EUN-YOUNG · 2016 to 2021
$1.7M
Role of FAK in vascular inflammationR01HL136432 · NHLBI · UNIVERSITY OF SOUTH ALABAMA · PI LIM, STEVE · 2017 to 2020
$1.6M
Assessing the EBV circular RNAomeR21CA236549 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI FLEMINGTON, ERIK K · 2019 to 2020
$362k
NCI NIH HHS R01 CA190688NCI NIH HHS R01 CA236911NCI NIH HHS R01 CA243793NCI NIH HHS R21 CA236549NHLBI NIH HHS R01 HL136432
6 · The paper itself

Abstract

A high incidence of acute megakaryoblastic leukemia (AMKL) in Down syndrome patients implies that chromosome 21 genes have a pivotal role in AMKL development, but the functional contribution of individual genes remains elusive. Here, we report that SON, a chromosome 21-encoded DNA- and RNA-binding protein, inhibits megakaryocytic differentiation by suppressing RUNX1 and the megakaryocytic gene expression program. As megakaryocytic progenitors differentiate, SON expression is drastically reduced, with mature megakaryocytes having the lowest levels. In contrast, AMKL cells express an aberrantly high level of SON, and knockdown of SON induced the onset of megakaryocytic differentiation in AMKL cell lines. Genome-wide transcriptome analyses revealed that SON knockdown turns on the expression of pro-megakaryocytic genes while reducing erythroid gene expression. Mechanistically, SON represses RUNX1 expression by directly binding to the proximal promoter and two enhancer regions, the known +23 kb enhancer and the novel +139 kb enhancer, at the RUNX1 locus to suppress H3K4 methylation. In addition, SON represses the expression of the AP-1 complex subunits JUN, JUNB, and FOSB which are required for late megakaryocytic gene expression. Our findings define SON as a negative regulator of RUNX1 and megakaryocytic differentiation, implicating SON overexpression in impaired differentiation during AMKL development.

Indexed as

Cell DifferentiationCore Binding Factor Alpha 2 SubunitDNA-Binding ProteinsDown SyndromeGene ExpressionGenetic Predisposition to DiseaseHumansLeukemia, Megakaryoblastic, AcuteMegakaryocytesMinor Histocompatibility AntigensTransfectionCore Binding Factor Alpha 2 SubunitDNA-Binding ProteinsMinor Histocompatibility AntigensRUNX1 protein, humanSON protein, human

Identifiers

PMID33247227
PMCPMC8155101
OpenAlexW3108133827

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.